Trial Profile
A 2-Part, Randomised, Placebo-Controlled, Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Study Of LAS190792 Delivered By Inhalation In Asthmatic And Chronic Obstructive Pulmonary Disease (COPD) Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jun 2019
Price :
$35
*
At a glance
- Drugs LAS 190792 (Primary) ; Indacaterol; Tiotropium bromide
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Almirall S.A.; AstraZeneca
- 25 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Feb 2014 New trial record